Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Periciazine→

Periciazine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2622-26-6
Molecular formula
C21H23N3OS
Molecular weight
365.5 g/mol
Drug class
First-generation phenothiazine antipsychoticsedative and behavioural-control agent
Mechanism of action
A phenothiazine with central dopaminergic and adrenergic antagonistic activity, together with anticholinergic and sedative effects. Its clinical pharmacology is consistent with first-generation phenothiazine antipsychotics.
Indications / reported uses
  • Adjunctive treatment in selected psychotic disorders, particularly where agitation, hostility or impulsive behaviour is a treatment concern, according to local product authorisation.

Sources: https://pubchem.ncbi.nlm.nih.gov/compound/4747 · https://pubchem.ncbi.nlm.nih.gov/compound/periciazine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Periciazine Environmental Risk Assessment (ERA) (the Periciazine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.